ARTICLE | Clinical News
Keytruda pembrolizumab regulatory update
November 16, 2015 8:00 AM UTC
FDA granted breakthrough therapy designation to Merck’s Keytruda pembrolizumab to treat patients with metastatic colorectal cancer with high levels of microsatellite instability. The pharma is evaluating the humanized IgG4 mAb against PD-1 based on microsatellite instability status in the pivotal Phase II KEYNOTE-164 trial. ...